Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-08-14
2007-08-14
Vogel, Nancy (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S358000, C536S023100, C536S023500, C435S069100
Reexamination Certificate
active
10048502
ABSTRACT:
The present invention provides isolated polypeptides of human p53 that contain mutations. These mutations can be toxic mutations, supertransactivating mutations or tox-suppressor mutations. Further provided by the invention are methods of identifying toxic, supertransactivating, weak transactivating and tox-suppressor mutations as well as methods of identifying compounds that mimic the toxic, supertransactivating and tox-suppressor mutations in human p53. Also provided are methods of inducing toxicity in a cell by administering a polypeptide comprising a supertransactivating or a toxic mutation.
REFERENCES:
patent: WO 96/16989 (1996-06-01), None
patent: WO 97/41136 (1997-11-01), None
patent: WO 00/22115 (2000-04-01), None
patent: WO 00/68384 (2000-11-01), None
patent: WO 01/09325 (2001-02-01), None
Schwartz et al. Curr. Opin. Mol. Ther. 2:162-167, 2000.
Schwarze et al. TICB 10: 290-295, 2000.
Zhang, W., Development and application of adenoviral vectors for gene therapy of cancer, Cancer Gene Therapy 6(2):113-138.
Brachmann et al. “Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations”EMBO J.17(7):1847-1859, 1998.
Bullock et al. “Quantiative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy”Oncogene19:1245-1256, 2000.
Bulliock et al. “Thermodynamic stability of wild-type and mutant p53 core domain”Proc. Natl. Acad. Sci. USA94:14338-14342, 1997.
Candau et al. “Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity”Oncogene15:807-816, 1997.
Caron de Fromentel et al. “Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments”Oncogene18:551-557, 1999.
Chene et al. “Mutations at position 277 Modify the DNA-Binding Specificity of Human p53 in vitro”Biochem. Biophys. Res. Commun.263:1-5 (1999).
Cho et al. “Crystal structures of a p53 tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations”Science265:346-355, 1994.
Conseiller et al. “CTS1: A p53-derived Chimeric Tumor Suppressor Gene with Enhanced In Vitro Apoptotic Properties”J. Clin. Invest.101(1):120-127, Jan. 1998.
Di Como and Prives “Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay”Oncogene16:2527-2539 (1998).
Flaman et al. “Identification of human p53 mutations with differential effects of the bax and p21 promoters using functional assays in yeast”Oncogene16:1369-1372 (1998).
Flaman et al. “A simple p53 functional assay for screening cell lines, blood, and tumors”Proc. Natl. Acad. Sci. USA92(9):3963-3967, Apr. 1995.
Foster et al. “Pharmacological Rescue of Mutant p53 Conformation and Function”Science286:2507-2510 (1999).
Freeman et al. “Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein”EMBO J.13(22):5393-5400, 1994.
Gagnebin et al. “Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenuos or virally transduced p53 mutants with altered sequence-specificity”Oncogene16(5):685-690, 1998.
Greenblatt et al. “Mutations in the p53 Tumor Suppresor Gene: clues to Cancer Etiology and Molecular Pathogenesis”Cancer Res. 54:4855-4878, 1994.
Gualberto et al. “An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control”Proc. Natl. Acad. Sci. USA95:5156-5171, 1998.
Hainaut et al. “IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools”Nucl. Acid Res. 26(1):205-213, 1998.
Hernandez-Boussard et al. “IARC P53 Mutation Database: A Relational Database To Compile and Analyze p53 Mutations In Human Tumors And Cell Lines”Hum. Mutat.14:1-8, 1999.
Inga et al. “N-(2-Chloroethyl)-N-Nitrosourea Tethered To Lexitropsin Induces Mirror Groove Lesion At The p53 Cdna That Are More Cytotoxic Than Mutagenic”Cancer Res. 59(3):689-695, 1999.
Ishioka et al. “Mutational analysis of the carboxy-terminal portion of p53 usig both yeast and mammalian cell assays in vivo”Oncogene10:1485-1492, 1995.
Kelly et al. “Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent”J. Biol. Chem.274(26):18327-18334, 1999.
Kern et al. “Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression” 256:827-830, 1992.
Ludwig et al. “Differential Activation of Target Cellular Promoters by p53 Mutants With Impaired Apoptotic Function”Mol. Cell. Biol.16(9):4952-4960, 1996.
Matsumura et al. “In vitro evolution of thermostable p53 variants”Protein Science8:731-740, 1999.
Nikolova et al. “Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations”EMBO J.19(3):370-378, 2000.
Saller et al. “Increased apoptosis induction by 121F mutant p53”EMBO J. 18(16):4424-4437, 1999.
Selivanova et al. “Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain”Mol. Cell Biol. 19(5:3395-3402, 1999.
Smith et al. “Novel p53 mutants selected in BRCA-associated tumors which dissociate transformation supression from other wild-type p53 functions”Oncogene18:2451-2459, 1999.
Soussi et al. “Structural Aspects of The p53 Protein In Relation To Gene Evolution: A Second Look”J. Mol. Biol.260:623-637, 1996.
Thukral et al. “Discrimination of DNA Binding Sites by Mutant p53 Proteins”Mol. Cell. Biol.15(9):5196-5202, Sep. 1995.
Venot et al. “Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains”Oncogene18;2405-2410, 1999.
Walker et al. “Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features”Oncogene19:211-218, 1999.
Wieczorek et al. “Structure-based rescue of common tumor-derived p53 mutants”Nat. Med.2:1143-1146, 1996.
Inga Alberto
Resnick Michael A.
Needle & Rosenberg P.C.
Schlapkohl Walter
The United States of America, as represented by the Secretary, D
Vogel Nancy
LandOfFree
Human p53 mutations and a genetic system in yeast for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human p53 mutations and a genetic system in yeast for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human p53 mutations and a genetic system in yeast for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3898797